Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical company Intelliject has received the US Food and Drug Administration (FDA) approval for its Auvi-Q (epinephrine injection, USP) used in the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis.
Subscribe to our email newsletter
According to Intellioject, Auvi-Q is the only compact auto-injector with audio and visual cues, which will guide patients and caregivers step-by-step through the injection process.
Intelliject chief science officer Eric Edwards said in developing Auvi-Q, the company’s goal is to offer patients and caregivers an innovative treatment option that is easy to use in an emergency.
”Auvi-Q’s small size and intuitive design, as well as its first-in-class prompt system that talks a user through the injection process, will help patients and caregivers manage a life-threatening allergic reaction," Edwards added.
Auvi-Q contains epinephrine used to treat severe, life-threatening allergic reactions that may occur as a result of exposure to allergens, which include nuts, shellfish, dairy, eggs, insect bites, latex and medication and others.
Intelliject president and CEO Spencer Williamson said the FDA approval of Auvi-Q is an important milestone for the company and is a result of our steadfast commitment to developing patient-centric products.
"We are building on this approval and have a pipeline of drug/device combination products for select therapy areas," Williamson added.